Melinta Therapeutics

Company Listings from SPi: Melinta Therapeutics

You are here: Home >> SPi Company Listings >> Melinta Therapeutics

 

Melinta Therapeutics

Website:
http://

Search for other references to "melinta" on SPi News

Latest Melinta Therapeutics News

Melinta Therapeutics to Present at the JMP Securities Life Sciences Conference NEW HAVEN, Conn., June 13, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibio...... 21:05 GMT Wednesday 13th June 2018

Melinta Therapeutics Demonstrates Breadth of Commercial and Clinical Programs with 20 Presentations at ASM Microbe 2018 NEW HAVEN, Conn., May 31, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibio...... 13:00 GMT Thursday 31st May 2018

Melinta Therapeutics Announces Closing of Underwritten Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock NEW HAVEN, Conn., May 29, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiot...... 21:05 GMT Tuesday 29th May 2018

Melinta Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference NEW HAVEN, Conn., May 24, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiot...... 13:00 GMT Thursday 24th May 2018

Melinta Therapeutics Announces Pricing of Public Offering of Common Stock NEW HAVEN, Conn., May 23, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiot...... 02:07 GMT Thursday 24th May 2018

Melinta Therapeutics Announces Proposed Offering of Common Stock NEW HAVEN, Conn., May 21, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiot...... 21:10 GMT Monday 21st May 2018

Melinta Therapeutics Launches New Antibiotic Stewardship Program to Combat Growing Threat of Antimicrobial Resistance NEW HAVEN, Conn., May 11, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiot...... 13:00 GMT Friday 11th May 2018

Melinta Therapeutics Reports First Quarter 2018 Financial Results NEW HAVEN, Conn., May 08, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiot...... 21:01 GMT Tuesday 8th May 2018

Melinta Therapeutics to Highlight Commitment to Antibiotics and Product Portfolio at MAD-ID 2018 Annual Meeting NEW HAVEN, Conn., May 08, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiot...... 13:00 GMT Tuesday 8th May 2018

Melinta Therapeutics Receives Up to $6.2 Million from CARB-X to Advance Clinical Development of a Novel Antimicrobial to Combat Antibiotic-Resistant Bacteria NEW HAVEN, Conn., May 07, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiot...... 12:00 GMT Monday 7th May 2018

Buy Melinta Therapeutics
Market Reports
from SPi

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us
 

Advertising on SPi News: Information For Advertisers